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ABSTRACT
Objective: To summarise existing systematic reviews
that assess the effects of non-pharmacological,
pharmacological and alternative therapies on activities
of daily living (ADL) function in people with dementia.
Design: Overview of systematic reviews.
Methods: A systematic search in the Cochrane
Database of Systematic Reviews, DARE, Medline,
EMBASE and PsycInfo in April 2015. Systematic
reviews of randomised controlled trials conducted in
people with Alzheimer’s disease or dementia
measuring the impact on ADL function were included.
Methodological quality of the systematic reviews was
independently assessed by two authors using the
AMSTAR tool. The quality of evidence of the primary
studies for each intervention was assessed using
GRADE.
Results: A total of 23 systematic reviews were
included in the overview. The quality of the reviews
varied; however most (65%) scored 8/11 or more on
the AMSTAR tool, indicating high quality. Interventions
that were reported to be effective in minimising decline
in ADL function were: exercise (6 studies, 289
participants, standardised mean difference (SMD) 0.68,
95% CI 0.08 to 1.27; GRADE: low), dyadic
interventions (8 studies, 988 participants, SMD 0.37,
95% CI 0.05 to 0.69; GRADE: low) acetylcholinesterase
inhibitors and memantine (12 studies, 4661
participants, donepezil 10 mg SMD 0.18, 95% CI 0.03
to 0.32; GRADE: moderate), selegiline (7 studies, 810
participants, SMD 0.27, 95% CI 0.13 to 0.41; GRADE:
low), huperzine A (2 studies, 70 participants, SMD
1.48, 95% CI 0.95 to 2.02; GRADE: very low) and
Ginkgo biloba (7 studies, 2530 participants, SMD 0.36,
95% CI 0.28 to 0.44; GRADE: very low).
Conclusions: Healthcare professionals should ensure
that people with dementia are encouraged to exercise
and that primary carers are trained and supported to
provide safe and effective care for the person with
dementia. Acetylcholinesterase inhibitors or memantine
should be trialled unless contraindicated.
Trial registration number: CRD42015020179.
INTRODUCTION
Dementia affects approximately 35.6 million
people worldwide.1 This ﬁgure is expected
to nearly double every 20 years due to
population ageing.2 It is one of the leading
causes of mortality and morbidity, particularly
in people aged 60 years or over in which
it affects approximately 5–7% of the
population.1
The trajectory of dementia is associated
with gradual functional decline whereby the
person with dementia requires more as-
sistance to manage activities over time due to
cognitive and physical impairment.
Functional decline is associated with reduced
quality of life in people with dementia3 and
increased care costs.4 It is also associated with
increased need for informal care and can
increase the carer burden, particularly when
the rate of decline is rapid.5
While dementia is a terminal condition,
the length of time between diagnosis and
death can be many years.6 Therefore, one of
the goals of treatment, particularly in the
earlier stages of the disease, is to promote in-
dependence and reduce functional decline.7
Consumers have called for a greater focus on
rehabilitation and restorative care in order to
maximise the quality of life.8
There are a number of intervention ap-
proaches that have been trialled to manage the
symptoms of dementia including pharmaco-
logical approaches (such as acetylcholinesterase
Strengths and limitations of this study
▪ This overview examines the efficacy for a
number of different treatment approaches in
delaying functional decline.
▪ The effect sizes of the different treatment
approaches are compared providing clinicians
and policymakers with information regarding
treatments that should be prioritised.
▪ The quality of the included reviews is appraised
using AMSTAR and the quality of evidence for
each intervention is appraised using GRADE.
▪ There is a debate regarding the most appropriate
methodology for conducting overviews including
how authors should capture the most recent evi-
dence and avoid including overlapping reviews.
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inhibitors) and non-pharmacological approaches (such
as exercise). The vast amount of research literature
means that it can be difﬁcult for health professionals to
keep themselves up to date in understanding which in-
terventions are thought to be effective overall and the
relative efﬁcacy of different intervention approaches.
Systematic reviews of systematic reviews (overviews) are
useful in that they examine the effectiveness of a number
of different interventions for a particular health condi-
tion.9 Systematic reviews do not traditionally attempt to
do this due to time and resources involved in conducting
such a review.
The aim of this review was to summarise systematic
reviews that assess the effects of intervention for func-
tional decline in people with dementia.
METHODS
An a priori review protocol was developed and registered
on the PROSPERO International prospective register of
systematic reviews (http://www.crd.york.ac.uk/PROSPERO;
registration number CRD42015020179). The protocol pro-
vides full details of the methods used. There were no
changes made to the protocol during the review.
Inclusion and exclusion criteria
Types of studies
This overview included the most recent and comprehen-
sive systematic reviews. Systematic reviews were deﬁned
as ‘a review of the evidence on a clearly formulated
question that uses systematic and explicit methods to
identify, select and critically appraise relevant primary
research, and to extract and analyse data from the
studies that are included in the review’.10 In order to be
eligible, the systematic review must have included rando-
mised controlled trials (RCTs). Cochrane Reviews and
systematic reviews published in other peer-reviewed jour-
nals were eligible. Systematic reviews that overlapped
with the most up to date and comprehensive review in
terms of the intervention approach were excluded to
avoid double counting of studies where possible. Reviews
published in non-English languages were excluded.
Population
Reviews which included populations of people with a
diagnosis of dementia (any cause) or Alzheimer’s
disease were included. Reviews were excluded if they
included people with non-Alzheimer’s dementia only
(eg, people with vascular dementia). Studies conducted
in any setting, whether community or residential, were
included.
Intervention and comparison
All interventions intended to treat or manage the symp-
toms of dementia were eligible; this included non-
pharmacological interventions (such as exercise, coun-
selling or education), pharmacological interventions
(such as acetylcholinesterase inhibitors) and alternative
therapies (such as Ginkgo biloba). Reviews including
RCTs which compared the intervention to usual care,
placebo or another form of intervention were included.
Outcome
The overview included reviews where performance of
global activities of daily living (ADL) was reported as a
primary or secondary outcome. ADL whether mea-
sured by observation, self-report or proxy report or
tools such as the Functional Independence Measure,
Barthel Index, Alzheimer’s Disease Co-operative Study
—ADL Inventory, Disability Assessment for Dementia
or Cleveland Scale for ADL were eligible.
Search methods for identification of reviews
Searches were conducted in the Cochrane Database of
Systematic Reviews Dementia and Cognitive Improvement
Group domain, Cochrane DARE, Medline, EMBASE and
PsycINFO in April 2015. The Medline search strategy
is attached as an online supplementary ﬁle and was
adapted for the other databases. The search strategy was
formulated including the dementia search string used by
the Cochrane Dementia and Cognitive Improvement
Group for dementia.
Data collection and analysis
Selection of reviews
One author (KL) conducted the searches and assessed
all retrieved citations meeting the inclusion criteria on
the basis of title and abstract. A second author (SD)
independently reviewed 10% of the excluded articles.
Potentially eligible reviews were reviewed in full text.
Two authors (KL and SD) independently assessed all
articles obtained in full text. A third author was con-
sulted in cases of disagreement. Eligible reviews were
classiﬁed based on intervention approach (eg, exercise)
and discussion occurred regarding the most appropriate
review to include (based on recency and quality). We
used methods consistent with the Cochrane Handbook;
we did not repeat the searches, determine eligibility,
assess risk of bias, conduct additional meta-analysis or
aim to identify any additional studies.9 Thus, we ac-
cepted included reviews as being ‘complete’ and did not
check other reviews for missing studies.
Data extraction and management
One author (KL) extracted the data which was checked
by a second researcher. Disagreements were resolved by
a third author. A data collection form was developed
and tested prior to starting the review. Fields extracted
included review details (author, title, year), review aims,
inclusion criteria, date of last search and data from
included RCTs that provided a comparison to usual
care, placebo or another form of treatment. If the
review included data from RCTs and other study
designs, we extracted the data for the RCTs only. Where
RCTs and quasi-RCTs were included, we extracted only
the RCT data when possible (ie, when individually
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reported). We extracted details on the number of RCTs
included in the review, population size and character-
istics, intervention and comparator characteristics and
outcomes (on an individual study basis or pooled values
as reported in the included review). Authors of the
included reviews were not contacted for further
information.
Assessment of quality of included reviews
Two people (KL and a second researcher) independ-
ently assessed the methodological quality of the
included reviews using the AMSTAR checklist.11 The
AMSTAR checklist includes a number of criteria which
reﬂect whether the review was guided by a protocol,
whether there was duplicate study selection and data
extraction, the comprehensiveness of the search, inclu-
sion of grey literature, use of quality assessment, appro-
priateness of data synthesis and documentation of
conﬂict of interest. Disagreements regarding AMSTAR
score were resolved by discussion or a decision made by
a third author.
Assessment of quality of the body of evidence for each
intervention
GRADE was used to rate the quality of the evidence for
each intervention.12 The GRADE level was determined
based on information provided in the systematic review.
The level considers the risk of bias of included studies,
indirectness of evidence, inconsistency of results (hetero-
geneity), imprecision of results and possibility of publica-
tion bias.12
Data synthesis
Data was synthesised in tables and a narrative synthesis
was used to provide a summary of results. Effect sizes
were also expressed graphically using standardised mean
difference. Where meta-analysis had already been con-
ducted within the review, we used the meta-analysis per-
formed by the authors. We did not conduct additional
meta-analyses, however where the results were presented
as mean difference, we calculated the standardised
mean difference to enable comparison of effect sizes
across reviews.
RESULTS
The study selection process is presented in ﬁgure 1
(PRISMA). There were 23 systematic reviews meeting all
inclusion criteria and included in this overview.13–35 An
additional 10 reviews were identiﬁed that listed ADL as
an outcome of interest; however the reviews failed to
identify any applicable studies. These reviews were for
socially assistive robots, animal-assisted therapy, transcuta-
neous electrical nerve stimulation, social support groups
for the person with dementia, naftidrofuryl, respite care,
smart home technologies, metal protein-attenuating com-
pounds, ibuprofen and educational interventions for the
person with dementia.36–45 One review evaluated the
efﬁcacy of metrifonate, however identiﬁed serious harms
associated with use; metrifonate was since withdrawn from
the market.46 These reviews are not discussed further. In
most cases, the most recent comprehensive review (ie,
dementia or Alzheimer’s disease) reporting ADL out-
comes was deemed as being of acceptable quality for
inclusion. There were two intervention categories where
this was not the case. We excluded two reviews of cogni-
tive rehabilitation which were published more recently
than the included Cochrane Review but involved a search
date that was not as recent as the included review.47 48 We
also excluded two systematic reviews of exercise that were
published more recently than the included review. One
of the excluded reviews was of lower quality than the
Cochrane Review and included non-randomised trials,
but involved a search date that was 6 months more
recent.49 A second review included studies where exercise
was included as one component of a multifactorial
programme.50
Characteristics of the included reviews
Characteristics of the included reviews are summarised
in table 1. Fifteen (65%) of the reviews were Cochrane
Reviews. Eleven reviews addressed non-pharmacological
approaches. These were cognitive training, cognitive
stimulation therapy, light therapy, exercise, aromather-
apy, nutritional supplementation, validation therapy, psy-
chological treatment, case management, music therapy
and intervention for the person with dementia and
carer dyad. Eight reviews addressed pharmacological
approaches. These were acetylcholinesterase inhibitors
and memantine, pharmacotherapies to improve sleep,
latrepirdine, melatonin, statins, selegiline, lecithin and
nimodipine. Four reviews addressed alternative therap-
ies. These were vitamin B supplementation, G. biloba,
huperzine A and acupuncture.
Most (65%) of the reviews included people with any
form of dementia. The remaining reviews included only
people with Alzheimer’s disease. The mean age of parti-
cipants in all reviews was people in their 70s or 80s with
the exception of the G. biloba and huperzine A reviews
which involved younger participants. Most participants
had mild-to-moderate severity dementia, although some
reviews of pharmacological interventions (eg, acetylcho-
linesterase inhibitors) included a large number of parti-
cipants with severe dementia. The duration of different
interventions varied from days to months and a large
number of outcome assessment measures were used to
assess ADL function.
Methodological quality of included reviews
The quality of the included review reﬂects the rigour
and transparency of the review team rather than the
quality of evidence for the intervention approach. Most
of the reviews (65%) were of high quality (scores ≥8/
11) as assessed using the AMSTAR tool (table 1).
High-quality reviews were for latrepirdine, light therapy,
exercise, aromatherapy, pharmacotherapies for sleep,
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case management, cognitive stimulation therapy, huper-
zine A, lecithin, selegiline and nimodipine. However,
there were also two lower quality reviews (scoring 5 or
less on AMSTAR). Low-quality reviews were for G. biloba
and dyadic interventions.
Quality of evidence in included reviews
While the authors of this overview did not reassess the
risk of bias of primary studies included in the reviews, it
was necessary to examine the quality of these studies as
determined by the original review authors to determine
the overall quality of the evidence using GRADE. It can
be seen from ﬁgure 2 that studies in most of the reviews
had a risk of bias resulting in downgrading of the quality
overall.
The quality of evidence for all non-pharmacological
interventions was low with the exception of nutritional sup-
plementation for which the evidence base was of moderate
quality. The quality of evidence for pharmacological
interventions ranged from low (latrepirdine) to high
(statins). In contrast, alternative therapies had very low
(huperzine A, G. biloba, acupuncture)-to-moderate (vita-
mins B) evidence.
EFFECT OF INTERVENTIONS
Effects are presented in table 2. Non-pharmacological
interventions: two non-pharmacological interventions
demonstrated a signiﬁcant effect in reducing to func-
tional decline in people with dementia. Exercise had a
large magnitude of effect (six studies, 289 participants,
SMD 0.69, 95% CI 0.08 to 1.27) however the quality of
evidence was low due to a risk of bias in some studies
and the limited number of participants in the analysis.
Dyadic interventions, in which the therapeutic interven-
tion aims to engage the person with dementia and their
carer in maximising quality of life (utilising interven-
tions, deﬁned broadly as psychosocial but which also
included meaningful activities, daily living activities and
Figure 1 PRISMA 2009 flow diagram.
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Table 1 Characteristics of included reviews
Review
Date of
search Population included in the review
Intervention addressed
in the review
Comparison
intervention Measures of ADL
Quality of the
review
(AMSTAR)
Non-pharmacological interventions
Forbes Oct 2013 Older people (over 65 years of age) and
diagnosed as having dementia using
accepted criteria
Mean age ranged from 73 to 89
Baseline MMSE ranged from 8 to 23
Exercise programmes Usual care or social
contact/activities
Barthel ADL index, Katz
Index of ADLs, Changes
in Advanced Dementia
Scale
10/11
Van’t Leven Jan 2012 Older people (aged 65 years or more)
with a diagnosis of dementia.
Participants were included if they were
living in informal carers in the community
and excluded if they were living in
residential care settings.
Mean age not reported though inclusion
criteria states >65.
Participants had mild-to-moderate
severity dementia.
Dyadic interventions Not specified Barthel Index
AMPS
IDDD
Functional Dependence
Scale
5/11
Neal Aug 2005 Older people (aged over 65 years)
diagnosed with Alzheimer’s disease,
dementia or other forms of cognitive
impairment
Nursing home residents with BPSD.
Mean age 88.
Validation therapy (affirming
the person’s beliefs and
experiences)
Usual care or
alternative
intervention (eg,
social contact group)
Not specified 7/11
Orgeta Jan 2013 Older people (aged over 65 years)
diagnosed with Alzheimer’s disease or
other forms of dementia
Mean age range 75–76
Mean MMSE range 22–24
Psychological treatments for
depression and anxiety
Usual care or
non-specific
psychosocial therapy
Bristol Activities of Daily
Living
ADSC-ADL
8/11
Reilly March 2014 Diagnosis of dementia of any subtype
and of any severity
Mean age range 78–80
Most participants had mild-to-moderate
severity dementia
Case management Usual care or
alternative
intervention
Everyday Abilities Scale
for India
ADCS-ADL
Barthel Index
9/11
Ueda Feb 2011 Diagnosis of dementia of any type
according to accepted criteria.
Mean age 83
Severity not reported
Music therapy Not specified Barthel Index 7/11
Woods Dec 2011 Diagnosis of dementia or any subtype
and of any severity.
Mean age range 74–85
Mean MMSE range 20–22
Cognitive stimulation
intervention targeting
cognitive and social
functioning
No treatment, usual
care or placebo
Barthel Index
IADL
Stewart ADL Scale
10/11
Continued
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Table 1 Continued
Review
Date of
search Population included in the review
Intervention addressed
in the review
Comparison
intervention Measures of ADL
Quality of the
review
(AMSTAR)
Bahar
Fuchs
Nov 2012 Diagnosis of dementia. Targeting people
with minimal, mild or moderate dementia
(MMSE>12)
Mean age was 78 in the studies
reporting this info.
Baseline MMSE range 23–25/30
Cognitive training or
cognitive rehabilitation
No treatment, usual
care, wait list control
or active control
Basic and Instrumental
Activities of Daily Living
scales
Physical Self
Maintenance Scale
Bayer Activities of Daily
Living Scale
8/11
Forbes Jan 2014 Diagnosis of dementia (all types
considered) according to accepted
criteria
Mean age 85, all participants were
nursing home residents
Light therapy Not specified Nurse-Informant Activities
of Daily Living Measure
10/11
Forrester Jan 2014 Diagnosis of dementia of any subtype
and of any severity
Mean age 85
Nursing home residents with agitation for
>4 weeks
Aromatherapy Placebo
aromatherapy
Barthel ADL Scale 9/11
Liu Sept 2012 Older people (over 65 years of age) and
diagnosed as having dementia using
accepted criteria
Mean age range 73–79
MMSE not reported in two of the three
studies in the review. The third study
involved people with mild Alzheimer’s
disease
Mealtime interventions (incl.
nutritional supplementation)
Not specified ADCS-ADL 8/11
Pharmacological interventions
Tan Nov 2013 Diagnosis of probable or possible
Alzheimer’s disease consistent with
accepted criteria
Mean age participants 76
Five of the trials included people with
mild-to-moderate dementia. Seven trials
included people with severe dementia
Acetylcholinesterase
inhibitors and memantine
Placebo ADCS-ADL 7/11
Chau June 2014 Clinical diagnosis of mild, moderate or
severe AD
Population age and severity not
described
Latrepirdine Placebo ADCS-ADL 10/11
Jansen June 2009 Diagnosis of dementia of any subtype
and of any severity
Mean age 85–86
Moderate severity dementia
Melatonin Placebo or no
treatment
Nurse-Informant Activities
of Daily Living Measure
8/11
Continued
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Table 1 Continued
Review
Date of
search Population included in the review
Intervention addressed
in the review
Comparison
intervention Measures of ADL
Quality of the
review
(AMSTAR)
McCleery March 2013 People who had both:
A. Alzheimer’s disease diagnosed using
any well-validated criteria, such as
DSM, at the time of the study, and
B. a sleep problem diagnosed on the
basis of subjective or objective
measures
Mean age ranged 77–81
Mean MMSE range 11–14
Pharmacotherapies for sleep Placebo Katz Index 10/11
McGuinness Jan 2014 Patients with a diagnosis of probable or
possible AD according to accepted
criteria.
Mean age 74–79
Mild-to-moderate severity dementia
Statins Placebo ADCS-ADL
ADFACS
7/11
Birks July 2002 Diagnosis of probable Alzheimer’s
disease
Mean age ranged from 70 to 83 in the
studies reporting ADL outcomes
Studies included people with
mild-to-moderate dementia
Selegeline Placebo Unclear 9/11
Birks March 2010 People with unclassified dementia,
Alzheimer’s disease, vascular dementia
or mixed dementia
Mean age ranged from 74 to 80 in the
studies reporting ADL outcomes
Studies included people with
mild-to-moderate dementia
Nimodipine Placebo Unclear 9/11
Higgins May 2004 Diagnosis of dementia of any type
Mean age 74 years
Mild-to-moderate severity
Lecithin Placebo PADL Scale 9/11
Alternative therapies
Yang June 2013 Diagnosis of Alzheimer’s disease.
People with other forms of dementia
were excluded.
All studies but one conducted in China
Age range 50–85
Details regarding severity of dementia
not reported
Huperzine A No treatment, usual
care or placebo.
Activities of Daily Living
Scale
ADCS-ADL
9/11
Tan March 2014 Diagnosis of dementia of any type or
people with mild cognitive impairment
Gingko biloba Placebo ADL-IS
GBS-ADL
3/11
Continued
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environmental adaptations) were also associated with a
signiﬁcant positive effect on ADL (eight studies, 988 par-
ticipants, SMD 0.37, 95% CI 0.05 to 0.69). Again, a
number of studies were at risk of bias and there were
mixed ﬁndings among studies. There was insufﬁcient
evidence to conclude whether or not the other interven-
tion approaches were effective due to the small number
of studies and the low quality of evidence.
Pharmacological interventions: two pharmacological
interventions demonstrated a signiﬁcant effect on ADL
function. The use of acetylcholinesterase inhibitors or
memantine was associated with a small but statistically
signiﬁcant effect on function (12 studies, 4661 partici-
pants, donepezil 5 mg SMD 0.18, 95% CI 0.10 to 0.46;
donepezil 10 mg SMD 0.18, 95% CI 0.03 to 0.32; galan-
tamine 24 mg SMD 0.15, 95% CI 0.04 to 0.25; rivastig-
mine 12 mg SMD 0.19, 95% CI 0.02 to 0.36). Overall,
the evidence for acetylcholinesterase inhibitors and
memantine was of moderate quality. Effect sizes varied
slightly according to the speciﬁc agent and dose used,
although the effect size was consistently small. Selegiline
was also found to have a small statistically signiﬁcant
effect on ADL function at 8–17-week follow-up (seven
studies, 810 participants, SMD 0.27, 95% CI 0.13 to
0.41). Studies were at risk of bias and there were mixed
ﬁndings between studies hence the quality of evidence
was low.
Alternative therapies: two of the alternative therapies
were reported to signiﬁcantly improve ADL function.
Huperzine A was reported to be effective although this
was based on only two studies (two studies, 70 partici-
pants, SMD 1.48, 95% CI 0.95 to 2.02). Furthermore,
the studies included in the review were at a high risk of
bias due to unclear allocation concealment, possible
selective reporting and risk of incomplete outcome data
in both of the studies, and possible non-blinded
outcome assessor in one of the studies. In addition, the
outcome measure used in the pooled analysis in the
review is not clearly reported. Overall, the quality of evi-
dence for huperzine A was considered very low. G. biloba
was also reported to be effective in the included system-
atic review, however it was also associated with very low-
level evidence; the quality of the systematic review
(AMSTAR=3/11) and the included studies was low
(seven studies, 2530 participants, SMD 0.36, 95% CI 0.28
to 0.44). Furthermore, although there were seven
included studies in the review, the ﬁndings were incon-
sistent between the studies.
DISCUSSION
This overview identiﬁed 23 systematic reviews (including
84 studies reporting on ADL performance outcomes).
These reviews addressed a range of different interven-
tions that may be considered for use in people with
dementia. Of the 23 interventions reviewed, only six
were reported to be successful in reducing functional
decline. Acetylcholinesterase inhibitors and memantine,
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pharmacological agents that are widely used in treating
dementia, were convincingly demonstrated to improve
the ADL (based on moderate quality evidence),
although the effect sizes were small. The quality of the
evidence was considered low for two non-
pharmacological approaches (exercise and dyadic psy-
chosocial interventions), however the effect sizes were
small-to-moderate, suggesting that more research is
required to conﬁrm effect on ADL. Evidence was very
low for the two alternative therapies (huperzine A and
G. biloba) indicating that the ﬁndings of improving ADL
should be interpreted with extreme caution for these
therapies. In addition, we found insufﬁcient evidence to
conclude that the remaining intervention approaches
are ineffective due to the lack of studies examining each
approach and poor methodological quality of existing
studies. While caution is required, due to the absence of
effective treatment options and trajectory of functional
decline associated with dementia, it is recommended
that after consideration of potential beneﬁts, harms and
costs, health professionals consider prescription of acet-
ylcholinesterase inhibitors/memantine as a method of
reducing functional decline. Furthermore, the effects of
exercise and dyadic interventions are thought to be
greater and they are not associated with side effects,
therefore these interventions should be routinely recom-
mended for people with dementia.
The magnitude of the effect sizes of the interventions
demonstrated to be effective were considered small to
moderate.51 Thus, while the intervention may signiﬁ-
cantly improve performance of the ADL, the effect may
not be strong enough to impact on outcomes of institu-
tionalisation, carer impact or quality of life. Two recent
systematic reviews revealed that only a small number of
studies have been shown to improve quality of life for
people with dementia.52 53 The reviews found that carer
interventions and dyadic interventions for people living
in private dwellings and cognitive stimulation therapy
for people in group homes had the best evidence for
positively impacting on quality of life.52
The number of studies, particularly of pharmaco-
logical agents, that measured the impact on ADL was
generally small. Interventional studies in dementia
research frequently focus on outcomes of cognitive func-
tion as the key symptoms of dementia, particularly in the
earlier phases of the condition, are cognitive. However,
studies should also examine impact on ADL function as
improvements in cognitive function may not translate to
gains in ADL performance or other patient-important
outcomes such as quality of life. For example, the
included review of acetylcholinesterase inhibitors and
memantine included 23 studies of which only 12 looked
at the effect of the interventions on ADL function.27
Similarly, the included review of exercise comprised 16
RCTs; nine of the studies reported cognitive outcomes,
whereas only six reported ADL function outcomes
despite the expectation that this would be a key
expected outcome of any exercise programme.16
Figure 2 The effect of different treatment approaches on activities of daily living function in people with dementia.
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Table 2 Effects of interventions as reported in the included systematic reviews
Intervention and comparison intervention
Number of participants included in
the meta-analysis (studies)
Measure of
ADL
Effect measure (expressed as SMD or
MD)
Statistically
significant
Quality of the
evidence (GRADE)
Non-pharmacological interventions
Exercise programmes vs usual care
(postintervention)16
6 studies (289 participants) Multiple SMD 0.68 (0.08 to 1.27) Yes ⊕⊕○○
Low1a,3
Dyadic interventions vs control30 8 studies (988 participants) Multiple SMD 0.37 (0.05 to 0.69) Yes ⊕⊕○○
Low1b,2
Validation therapy vs usual care (1 year)24 1 study (88 participants) Unclear Review stated effect on ADL was not
significant (data not reported)
No ⊕⊕○○
Low1c,3
Psychological treatments for depression and
anxiety vs usual care (postintervention
(6 weeks/8–12 months))25
2 studies (313 participants) Multiple SMD −0.13 (−0.35 to 0.09) No ⊕⊕○○
Low1b,3
Case management vs usual care
(6 months)26
3 studies (318 participants) Multiple SMD −0.03 (−0.25 to 0.19) No ⊕⊕○○
Low1d,3
Music therapy vs control (postintervention)
B29
6 studies (195 participants) Multiple SMD 0.05 (−0.23 to 0.34) No ⊕⊕○○
Low1e,3
Cognitive stimulation vs no cognitive
stimulation (postintervention)31
4 studies (260 participants) Multiple SMD 0.21 (−0.05 to 0.47) No ⊕⊕○○
Low1f,3
Cognitive training vs control
(postintervention)13
4 studies (107 participants) Multiple SMD 0.00 (−0.38 to 0.38) No ⊕⊕○○
Low1g,3
Light therapy vs control (at 1 year)15 1 study (94 participants) NI-ADLs MD −5.0 (−11.16 to 1.16)
Data not available for conversion to
SMD
No ⊕⊕○○
Low1h,3
Aromatherapy vs placebo
(postintervention)17
1 study (63 participants) Barthel Scale MD −0.50 (−1.79 to 0.79)
Data not available for conversion to
SMD
No ⊕⊕○○
Low1i,3
Nutritional intervention vs controlA
(postintervention (3 months))21
3 studies (1262 participants) Multiple Not pooled
The individual trials reported no
significant differences between the
groups
No ⊕⊕⊕○
Moderate1j
Pharmacological interventions
Acetylcholinesterase inhibitors and
memantine vs placebo at end point27
12 studies (4661 participants) ADCS/ADL
subscale
Donepezil 5 mg MD 1.0 (−0.53 to 2.53)
SMD 0.18 (−0.10 to 0.46)
Donepezil 10 mg MD 1.03 (0.21 to 1.85)
SMD 0.18 (0.03 to 0.32)
Galantamine 24 mg MD 0.68 (0.04 to
1.32) SMD 0.15 (0.04 to 0.25)
Rivastigmine 12 mg MD 1.8 (0.20 to
3.40) SMD 0.19 (0.02 to 0.36)
Memantine 20 mg MD 1.02 (0.27 to
1.78) SMD 0.11 (0.02 to 0.21)
Yes ⊕⊕⊕○
Moderate1k
Latrepirdine vs placebo (postintervention)14 3 studies (1243 participants) ADCS-ADL
Scale
MD 1.00 (−1.15 to 3.15)
SMD 0.06 (−0.06 to 0.17)
No ⊕⊕○○
Low1l,2
Melatonin vs placebo (6 weeks)18 1 study (86 participants) NI-ADLs MD −2.0 (−7.50 to 3.50)
SMD −0.15 (−0.58 to 0.27)
No ⊕⊕⊕○
Moderate3
Pharmacotherapies for sleep vs placebo
(melatonin, trazodone) (postintervention
(2–8 weeks))22
2 studies (193 participants) Multiple Not pooled
The individual trials reported no
significant differences between the
groups
No ⊕⊕⊕○
Moderate3
Continued
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Table 2 Continued
Intervention and comparison intervention
Number of participants included in
the meta-analysis (studies)
Measure of
ADL
Effect measure (expressed as SMD or
MD)
Statistically
significant
Quality of the
evidence (GRADE)
Statins vs placebo (3 months)23 3 studies (1109 participants) Multiple Not pooled
The individual trials reported no
significant differences between the
groups
No ⊕⊕⊕⊕
High
Selegiline vs placebo (8–17 weeks)33 7 studies (810 participants) Multiple SMD 0.27 (95% CI 0.13 to 0.41) Yes ⊕⊕○○
Low1m,2
Nimodipine vs placebo (6 months)34 3 studies (1228 participants) Multiple SMD −0.12 (95% CI −0.23 to 0.00) No ⊕⊕⊕○
Moderate1m
Lecithin vs placebo (6 months)35 1 study (63 participants) PADL Scale The trial reported no significant
differences between the groups
No ⊕⊕⊕○
Moderate3
Alternative therapies
Huperzine A vs placebo (12 weeks)32 2 studies (70 participants) ADL Scale MD −8.82 (−11.47 to −6.16)C
SMD −1.48 (−2.02 to −0.95)
Yes ⊕⊕○○
Very low3,4
Gingko biloba vs placebo (endpoint)28 7 studies (2530 participants) Multiple SMD −0.36 (−0.44 to −0.28)D Yes ⊕⊕○○
Very low2,4
Acupuncture vs herbal mixture (8 weeks)19 1 study (104 participants) Not reported ES=0.29, not significant No ⊕⊕○○
Very low3,4
Vitamins B supplementation vs control
(postintervention (6–18 months))20
3 studies (481 participants) Multiple SMD 0.13 (−0.05 to 0.31) No ⊕⊕⊕○
Moderate1n
A. Note the nutritional interventions included daily oral nutritional supplementation, medical food (Souvenaid) and a health and nutrition promotion programme for physicians, caregivers and
people with dementia.
B. Note that the meta-analysis conducted in the systematic review by Ueda and colleagues included randomised and non-randomised trials.
C. The authors report this outcome as an ADL Scale but do not specify the particular scale. A lower score in the meta-analysis was interpreted by the authors as an improvement in ADL
function.
D. The authors reported this reduction in score as an improvement in function. Examination of the meta-analysis suggests that outcome measures were combined. Where outcome measures
used higher scores to represent better function, the scores were multiplied by −1 so that all outcome measures were reporting in the same direction in the meta-analysis.
Note: Where MD was reported, the authors of the review calculated the SMD in RevMan.
GRADE footnotes.
1aUnclear randomisation procedures in three studies. Unclear whether outcome assessor blinded in one study. Participants not blinded. Downgraded for risk of bias.
1bUnclear whether outcome assessor blinded in one study. Participants not blinded. Downgraded for risk of bias.
1cUnclear allocation concealment. Participants not blinded. Downgraded for risk of bias.
1dUnclear allocation concealment in one study. Participants not blinded. Outcome assessors not blinded or status unclear in two studies. Selective reporting in one study. Downgraded for risk of
bias.
1eUnclear allocation concealment and blinding in two studies. Incomplete outcome data in two studies. Participants not blinded. Downgraded for risk of bias.
1fUnclear allocation concealment, randomisation sequence generation, incomplete outcome data and details of blinding in two studies. Downgraded for risk of bias.
1gRandomisation details unclear in all four studies. Details of incomplete outcome data and blinded outcome assessor unclear in single studies (×2). Participants not blinded. Downgraded for
risk of bias.
1hCluster randomisation by care home. Downgraded for risk of bias.
1iUnclear allocation concealment and unclear risk due to incomplete outcome data. Downgraded for risk of bias.
1jTwo of the three studies were rated as being of moderate quality while the remaining study was rated as strong. Downgraded for risk of bias.
1kMixed quality of studies and variability in transparency of reporting. Downgraded for risk of bias.
1lHigh risk of bias for incomplete outcome data and selective reporting in two studies. Unclear allocation concealment in one study. Downgraded for risk of bias.
1mUnclear details of randomisation in all studies. Downgraded for risk of bias.
1nUnclear selective reporting and unclear risk of bias in other areas reported for one study. Downgraded for risk of bias.
2Mixed findings among studies, CIs do not overlap. Downgraded for inconsistency.
3Total number of participants <400 in the analyses. Downgraded for imprecision.
4Very serious risk of bias: unclear or high in majority of studies for most aspects of quality assessment. Downgraded (−2) for risk of bias.
ADCS, Alzheimer’s disease co-operative study; ADL, activities of daily living; ES, effect size; NI-ADL, nurse informant activities of daily living; PADL, physical ADL; SMD, standardised mean
difference; MD, mean difference.
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The interventions that were found to have a signiﬁcant
effect on ADL function should not be difﬁcult to imple-
ment routinely for people with dementia as they are
accessible in most Western countries. However, health
professionals should note that the non-pharmacological
interventions that were effective (exercise and dyadic
interventions) involved regular participation. Exercise
programmes ranged in frequency from 2 to 5 times per
week and were programmed over a minimum of
7 weeks. Dyadic interventions were scheduled over a
number of treatment sessions. It should be noted that
the interventions reduced functional decline relative to
the control group rather than leading to improvements
in functional performance compared with the baseline,
indicating a slowing of functional decline rather than
prevention.
The number of research trials evaluating the efﬁcacy
of acetylcholinesterase inhibitors is large relative to
research conducted in other aspects of dementia treat-
ment. Published studies consistently demonstrate a posi-
tive effect on cognition and ADL function. Clinicians
need to consider the potential bias of the research in
this ﬁeld given that many of the studies were funded by
pharmaceutical companies. Killin et al54 conducted a
meta-analysis examining the differences in ﬁndings
between industry-funded and independent RCTs of
donepezil and found that studies sponsored by pharma-
ceutical companies reported a larger effect on standar-
dised cognitive tests than independent research groups.
Policymakers should consider the results of this review
and implications for practice. For example, in Australia,
while the government spends a large amount of money
subsidising acetylcholinesterase inhibitors and meman-
tine (over $60 million per year55), there is less money
invested in ensuring people with dementia can access
appropriate exercise programmes or dyadic interven-
tions, which may be associated with other beneﬁts such
as improved cardiovascular health, reduced carer
burden and increased community participation.
The beneﬁt of conducting an overview is that it pro-
vides a wide-ranging perspective on the intervention
approaches available and their relative efﬁcacy. One of
the limitations of this approach is that the most recently
published primary studies are not captured. However,
the search dates of the included reviews were relatively
recent in most cases. Furthermore, while the body of
research for interventions in dementia care is slowly
accumulating, there have not been any signiﬁcant
advances in the past couple of years that would alter
routine care. Another limitation is that systematic
reviews tend to examine single-intervention approaches
and therefore more complex multifactorial interventions
(eg, physical exercise plus cognitive stimulation) have
not been captured. In addition, the detail of partici-
pants, intervention and results are less prominent at the
level of overview and there is a little scope to delve into
the details of the individual interventions. The ﬁndings
of this review suggest that clinicians should familiarise
themselves with the details of the type of exercise and
dyadic interventions thought to be most effective.16 30
This particular overview did not seek to identify add-
itional trials that may have been missed in the ‘included’
systematic review and excluded reviews in languages pub-
lished other than English. Furthermore, we only
included RCTs which restricted the number of studies
included and information that can be drawn upon. The
results of this overview highlight effective approaches
but do not provide much needed information around
cost-effectiveness as economic evaluations in dementia
care are scarce.56
There is clearly more work to be performed in both
developing interventions to delay functional decline and
testing interventions to provide more evidence around
the type of approaches that are most effective and for
whom. For example, the review on exercise failed to
provide recommendations about the type of exercise or
population most likely to beneﬁt due to the heterogen-
eity of studies.
In conclusion, at the current time in the absence of
disease-modifying treatments for dementia, health pro-
fessionals should attempt to minimise functional decline
in people with dementia by considering prescription of
acetylcholinesterase inhibitors and memantine, and
recommending exercise and dyadic interventions.
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